Study Probes How to Tell Elderly Patients Not to Bother With Cancer Screening
Over the past decades, the idea that all adults should get regularly screened for cancer — with mammograms, colonoscopies and prostate specific antigen blood tests — has been conveyed to the public time after time. But current clinical guidelines recommend against screening many older adults, such as those with less than 10 years’ life expectancy. For doctors, talking to a patient about the idea that they’ve “aged out” of cancer screening can be a challenging conversation.
Now, to better inform these conversations, Johns Hopkins researchers have studied the perspectives of both clinicians and older adults on how to communicate about stopping cancer screening. The results of this study were published in the June 2019 issue of The Gerontologist. In a separate study, other Johns Hopkins researchers also show that primary care doctors and specialists are equally likely to continue to order mammograms in women with less than 10 years’ life expectancy. Results of this study were published in the May 14 issue of the Journal of General Internal Medicine.
Mammograms, colonoscopies and prostate cancer screening have been credited with preventing cancer-related deaths by detecting cancers before they are advanced enough to cause severe symptoms. One study published online Feb. 11, 2019, for instance, concluded that mammograms have prevented up to 600,000 breast cancer deaths since 1990. But the screening methods also come with a cost; the U.S. health care system spends an estimated $7.8 billion on mammograms each year.
Studies have found that cancer screening in adults with limited life expectancy can present unnecessary risks and lead to unnecessary treatments. That’s because the tests may detect slow-growing tumors that aren’t likely to affect an older person’s lifespan. The U.S. Preventive Services Task Force currently recommends routine breast cancer screening for women ages 50–74 and colorectal cancer screening for adults ages 50–75. Above that age, the guidelines suggest that whether screening is beneficial depends on a person’s unique health situation. For prostate cancer screening, the guidelines suggests that whether or not to screen men ages 55–69 should be tailored to a person’s health situation and recommend against screening in other age groups. But how should doctors discuss this with patients when they reach the upper boundaries of routine cancer screening?
To better understand this conundrum, Schoenborn and her colleagues interviewed 28 clinicians and 40 older adults, ages 65–92, about their viewpoints on cancer screening discussions. The patients were recruited from four clinical programs associated with Johns Hopkins Bayview Medical Center and were 57.5% female, 62.5% white and had a range of educational levels and life expectancies. The clinicians included physicians, certified registered nurse practitioners and physician assistants who were all associated with Johns Hopkins Community Physicians. Interviews with clinicians were 40–60 minutes long and conducted between January and May 2015; interviews with patients were 30–60 minutes long and conducted in private offices, clinic rooms or patients’ homes between December 2015 and March 2016. All interviews were audio recorded and transcribed.
Schoenborn’s group reported that both clinicians and patients thought it was important to frame discussions around stopping cancer screening in terms of risks and benefits. While screening can reveal tumors, it can also lead to complications from screening — such as colon perforations during a colonoscopy — and to risks and side effects from follow-up tests and treatment — such as the infection, fatigue and bleeding associated with chemotherapy. Cancer diagnosis may also lead to diverted attention from other health priorities, increased psychological stress and a financial burden on patients.
Patients and clinicians also agreed that patients should play an active role in making the decision to stop screening. Clinicians tended to worry that patients might perceive the recommendation to stop screening in a negative light and that it would make patients angry. However, patients mostly responded that if they trusted their clinician, they would not think negatively of them for initiating the conversation.
“I hope that’s reassuring for doctors,” says Schoenborn. “And makes them a little bit more comfortable going into these conversations.”
While clinicians almost unanimously reported that they didn’t bring up life expectancy in the context of stopping cancer screening, older adults were split on the idea — some wanted to hear about life expectancy, others thought it was acceptable not to bring it up and a third group was actively against it.
“We’d like to continue to look in a larger population at preferred phrases to use in these discussions,” says Schoenborn. “There are still some challenges for clinicians learning how to talk about these things and we want to encourage discussion.”
In an effort to learn more about which physicians might be prescribing later-in-life screening, Schoenborn and her team turned to breast cancer screening and mammography. A commonly held belief was that specialists tend to order more screening mammograms than primary care clinicians. But, in the Journal of General Internal Medicine paper, Schoenborn and her team report that the type of doctor did not make a difference in whether a doctor continued to prescribe mammograms for patients past the life expectancy recommendation. They did find that internal medicine, family medicine and obstetrics/gynecologic specialists were the most common prescribers of mammograms to patients regardless of life expectancy.
Understanding which doctors are ordering mammograms in women who may not benefit from the screening tests can help researchers determine who to target with education, says Schoenborn.
For their study, Schoenborn and her colleagues used previously published data from the 2011 National Health and Aging Trends Study (NHATS) to identify 2,041 women age 65 and over who had no history of breast cancer to ask how many continued to have mammograms despite having limited life expectancy. Of the women in the study, 86% were white, 7.1% black and 3.9% Hispanic. Medicare data linked to NHATS let the researchers identify which patients had a mammogram in the 24 months following the NHATS survey and who had ordered that mammogram — a clinician in family medicine, internal medicine, other primary care, obstetrics and gynecology, or other specialties such as radiology or cardiology. The researchers calculated life expectancy using a previously validated life expectancy prediction model. They grouped patients into those with greater than 10 years’ life expectancy and fewer than 10 years’ life expectancy.
Among the 2,140 women, 48.0% received a screening mammogram during the study period, with a screening rate of 60.2% for women with a life expectancy of more than 10 years and 27.0% for women with a shorter life expectancy. The most common clinician specialties who referred women to get mammograms were internal medicine, family medicine, and obstetrics/gynecology. There was no significant difference in who referred mammograms for women with shorter versus longer life expectancies.
“If we already have a curriculum on communicating with patients about stopping cancer screening, then it’s not that much added cost to disseminate that to specialists as well as primary care providers,” she says.
In addition to Nancy Schoenborn, other authors on the Journal of General Internal Medicine paper are Jin Huang, Cynthia Boyd and Craig Pollack of Johns Hopkins and Sarah Newark of RAND Corporation. The work and researchers involved were supported by the American Cancer Society (CCCDA-16-002-01) and the National Institute on Aging (K76AG059984, 1K24AG056578).
Other authors on the Gerontologist paper are Cynthia Boyd, Danelle Cayea and Craig Pollack of Johns Hopkins and Sei Lee of the University of California, San Francisco. The work was supported by the National Institute on Aging (K23AG032910, K24AG056578, and R03AG050912), Atlantic Philanthropies, National Cancer Institute (K07CA151910), American Geriatrics Society, Daniel and Jeannette Hendin Schapiro Geriatric Medical Center, John A. Hartford Foundation, American Cancer Society (CCCDA-16-002-01), National Center for Advancing Translational Sciences (KL2TR001077), Alliance for Academic Internal Medicine and Maryland Cigarette Restitution Fund.